Aliases & Classifications for Endogenous Depression

MalaCards integrated aliases for Endogenous Depression:

Name: Endogenous Depression 12 15 71
Unipolar Depression 12 15 71
Clinical Depression 12 54 71
Depressive Disorder 43 71

Classifications:



External Ids:

Disease Ontology 12 DOID:1595
MeSH 43 D003866
UMLS 71 C0011573 C0011581 C0041696 more

Summaries for Endogenous Depression

Disease Ontology : 12 A mental depression that is characterized by a dysregulation of the endogenous opioid system and not of the monaminergic system.

MalaCards based summary : Endogenous Depression, also known as unipolar depression, is related to postpartum depression and depression, and has symptoms including depressed - symptom An important gene associated with Endogenous Depression is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Peptide ligand-binding receptors and CREB Pathway. The drugs Parathyroid hormone and Valsartan have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 74 Endogenous depression (melancholia) is an atypical sub-class of the mood disorder, major depressive... more...

Related Diseases for Endogenous Depression

Diseases related to Endogenous Depression via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 607)
# Related Disease Score Top Affiliating Genes
1 postpartum depression 32.0 SLC6A4 OXT MAOA LIPA HTR1A CRH
2 depression 31.6 SLC6A4 MAOA HTR2A HTR1A CRHR1 CRH
3 bipolar i disorder 31.2 SLC6A4 HTR2A HTR1A BDNF
4 major depressive disorder 31.1 TPH1 SLC6A4 OXT NR3C1 NPY MAOA
5 schizoaffective disorder 31.1 SLC6A4 INS HTR2A HTR1A BDNF
6 melancholia 30.9 SLC6A4 MAOA HTR2A HTR1A CRH BDNF
7 phobia, specific 30.9 SLC6A4 MAOA HTR1A
8 sexual disorder 30.9 SLC6A4 OXT INS HTR3A HTR2A HTR1A
9 adjustment disorder 30.8 SLC6A4 NPY HTR2A BDNF
10 diarrhea 30.8 SLC6A4 IL2 IL1B HTR3A
11 antisocial personality disorder 30.8 SLC6A4 MAOA HTR2A
12 social phobia 30.6 SLC6A4 OXT MAOA HTR3A HTR1A
13 paranoid schizophrenia 30.6 SLC6A4 MAOA HTR2A HTR1A BDNF
14 diabetes insipidus 30.6 OXT INS CRH
15 conduct disorder 30.6 TPH1 SLC6A4 MAOA
16 somatoform disorder 30.6 TPH1 SLC6A4 IL1B HTR3A BDNF
17 eating disorder 30.5 SLC6A4 NPY HTR2A CRH BDNF
18 somatization disorder 30.5 SLC6A4 OXT HTR2A HTR1A CRH
19 hyperprolactinemia 30.5 TRH INS HTR2A GNRH1
20 body dysmorphic disorder 30.5 SLC6A4 MAOA HTR2A
21 neurotic disorder 30.5 SLC6A4 MAOA INS HTR2A HTR1A BDNF
22 substance dependence 30.4 TPH1 SLC6A4 MAOA CRHR1 CRH BDNF
23 dissociative disorder 30.4 SLC6A4 OXT HTR2A
24 amnestic disorder 30.4 HTR3A HTR1A CREB1 BDNF
25 substance abuse 30.4 SLC6A4 NPY MAOA INS HTR2A HTR1A
26 psychotic disorder 30.4 TPH1 SLC6A4 OXT MAOA HTR3A HTR2A
27 pulmonary disease, chronic obstructive 30.3 SLC6A4 NR3C1 INS IL1B
28 premenstrual tension 30.3 HTR1A GNRH1
29 avoidant personality disorder 30.3 TPH1 SLC6A4 MAOA
30 thyroiditis 30.3 TRH INS IL2
31 amenorrhea 30.3 TRH NPY INS GNRH1 CRH
32 opiate dependence 30.3 TPH1 SLC6A4 CRH CREB1
33 craniopharyngioma 30.3 TRH INS GNRH1
34 tic disorder 30.2 SLC6A4 MAOA HTR2A
35 pathological gambling 30.2 TPH1 SLC6A4 MAOA HTR2A
36 acquired immunodeficiency syndrome 30.2 NR3C1 IL2 IL1B CRH
37 alexithymia 30.2 SLC6A4 OXT HTR1A
38 conn's syndrome 30.2 TRH NR3C1 GNRH1 CRH
39 agoraphobia 30.2 SLC6A4 MAOA HTR2A HTR1A
40 kleptomania 30.2 SLC6A4 MAOA HTR1A
41 intermittent explosive disorder 30.2 SLC6A4 MAOA HTR2A
42 attention deficit-hyperactivity disorder 30.1 TPH1 SLC6A4 OXT NR3C1 NPY MAOA
43 fragile x syndrome 30.1 SLC6A4 MAOA CRHR1 BDNF
44 heroin dependence 30.1 SLC6A4 MAOA BDNF
45 drug dependence 30.1 SLC6A4 NPY HTR3A CRHR1 CRH BDNF
46 serotonin syndrome 30.1 SLC6A4 OXT MAOA HTR3A HTR2A HTR1A
47 atypical depressive disorder 30.1 SLC6A4 NR3C1 MAOA HTR2A HTR1A CRHR1
48 neuroleptic malignant syndrome 30.1 HTR3A HTR2A HTR1A
49 hypoactive sexual desire disorder 30.1 OXT HTR2A HTR1A
50 sleep disorder 30.0 SLC6A4 INS HTR2A HTR1A BDNF

Graphical network of the top 20 diseases related to Endogenous Depression:



Diseases related to Endogenous Depression

Symptoms & Phenotypes for Endogenous Depression

UMLS symptoms related to Endogenous Depression:


depressed - symptom

MGI Mouse Phenotypes related to Endogenous Depression:

45 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.47 BDNF CREB1 CRH CRHR1 HTR1A HTR2A
2 homeostasis/metabolism MP:0005376 10.41 BDNF CREB1 CRH CRHR1 GNRH1 HTR1A
3 growth/size/body region MP:0005378 10.35 BDNF CREB1 CRH GNRH1 HTR3A IL1B
4 cardiovascular system MP:0005385 10.34 CREB1 CRHR1 HTR1A IL1B IL2 INS
5 endocrine/exocrine gland MP:0005379 10.34 BDNF CREB1 CRH CRHR1 GNRH1 HTR2A
6 nervous system MP:0003631 10.27 BDNF CREB1 CRH CRHR1 GNRH1 HTR1A
7 digestive/alimentary MP:0005381 10.25 BDNF GNRH1 HTR2A IL2 INS LIPA
8 integument MP:0010771 10.17 BDNF CRH GNRH1 HTR3A IL1B INS
9 adipose tissue MP:0005375 10.09 CRH INS LIPA NPY NR3C1 OXT
10 liver/biliary system MP:0005370 9.95 CRH GNRH1 IL2 INS LIPA NPY
11 no phenotypic analysis MP:0003012 9.92 BDNF CRH CRHR1 HTR1A IL2 INS
12 normal MP:0002873 9.91 BDNF CREB1 CRH CRHR1 GNRH1 INS
13 renal/urinary system MP:0005367 9.81 CRH GNRH1 HTR3A INS LIPA NPY
14 respiratory system MP:0005388 9.56 BDNF CREB1 CRH CRHR1 IL2 LIPA
15 skeleton MP:0005390 9.32 CREB1 CRH GNRH1 HTR2A IL1B INS

Drugs & Therapeutics for Endogenous Depression

Drugs for Endogenous Depression (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 619)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
2
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
3
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
4
Reboxetine Approved, Experimental Phase 4 71620-89-8, 98769-81-4 123628 65856
5
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
6
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
7
Amitriptyline Approved Phase 4 50-48-6 2160
8
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
9
Memantine Approved, Investigational Phase 4 19982-08-2 4054
10
Ziprasidone Approved Phase 4 146939-27-7 60854
11
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
12
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
13
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
14
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
15
Methohexital Approved Phase 4 151-83-7 9034
16
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
17
Propranolol Approved, Investigational Phase 4 525-66-6 4946
18
Desipramine Approved, Investigational Phase 4 50-47-5 2995
19
Methyltestosterone Approved Phase 4 58-18-4 6010
20
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
21
Testosterone enanthate Approved Phase 4 315-37-7 9416
22
Moclobemide Approved, Investigational Phase 4 71320-77-9 4235
23
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
24
Iloperidone Approved Phase 4 133454-47-4 71360
25
Terazosin Approved Phase 4 63590-64-7 5401
26
Prazosin Approved Phase 4 19216-56-9 4893
27
Zolpidem Approved Phase 4 82626-48-0 5732
28
Haloperidol Approved Phase 4 52-86-8 3559
29
Calcium carbonate Approved, Investigational Phase 4 471-34-1
30
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
31
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
32
Methadone Approved Phase 4 76-99-3 4095
33
Ribavirin Approved Phase 4 36791-04-5 37542
34
Sodium citrate Approved, Investigational Phase 4 68-04-2
35
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
36
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
37
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
38
Topiramate Approved Phase 4 97240-79-4 5284627
39
Isocarboxazid Approved Phase 4 59-63-2 3759
40
Protriptyline Approved Phase 4 438-60-8 4976
41
Trimipramine Approved Phase 4 739-71-9 5584 4055
42
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
43
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
44
Donepezil Approved Phase 4 120014-06-4 3152
45
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
46
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
47
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
48
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
49
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
50
Buspirone Approved, Investigational Phase 4 36505-84-7 2477

Interventional clinical trials:

(show top 50) (show all 4144)
# Name Status NCT ID Phase Drugs
1 Exploring Alterations of Central Autonomic Modulation in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
2 THE AIUNI - Integral Assessment in Unipolar Depression Unknown status NCT02268487 Phase 4 Sertraline
3 Phase 4 Study of Vitamin D3 Supplementation for Outcomes in Patients With Unipolar Depression Unknown status NCT01390662 Phase 4
4 Phase 4 Study of Escitalopram Treatment and Biomarkers in Major Depressive Disorder Unknown status NCT01997580 Phase 4 escitalopram
5 The Effect and Reliability of Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders Unknown status NCT03122158 Phase 4 Escitalopram
6 Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder Unknown status NCT01699490 Phase 4 Fluoxetine + Valsartan;Fluoxetine + Placebo
7 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo
8 Pharmacogenomics Studies of Antidepressants Unknown status NCT01204086 Phase 4 Venlafaxine;Fluoxetine
9 Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder Unknown status NCT02051413 Phase 4 Venlafaxine extended release
10 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
11 Dose Response Effects of Estrogen Augmentation in Mood & Memory in Perimenopausal Depression Unknown status NCT00229450 Phase 4 estrogen
12 Randomized,Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
13 Clinical Trial of the Use of Ketamine in Treatment Resistant Depression Unknown status NCT02610712 Phase 4 Ketamine
14 Phase 4 Study on the Effect of Partial Sleep Deprivation on Cognition and the IL-6-gp130-System in Individuals With Major Depression Unknown status NCT00291239 Phase 4
15 A Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Before and After Treatment With Desvenlafaxine Unknown status NCT02859103 Phase 4 Desvenlafaxine
16 Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder Unknown status NCT00442481 Phase 4 Escitalopram
17 Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine
18 Turgut Ozal Medical Center Department of Anesthesiology and Reanimation Unknown status NCT02267980 Phase 4 Sevoflurane;Ketamine;Saline
19 Inflammatory Markers and Cognitive Function in Major Depression:a Pilot Study Unknown status NCT01391221 Phase 4 Duloxetine
20 Duloxetine for the Treatment of Major Depression in Midlife Women: Effects on Brain Structure and Functioning, Mood, and Quality of Life Unknown status NCT00889369 Phase 4 Duloxetine
21 Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
22 A Randomised Trial Investigating the Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder. Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
23 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Escitalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Mirtazapine;Bupropion;Trazodone
24 White Matter Structure and Response to Treatment With Antidepressants: a Study of Desvenlafaxine in Major Depression. A Pilot Study Unknown status NCT01492621 Phase 4 Desvenlafaxine
25 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression. Unknown status NCT00335205 Phase 4 ropinirole
26 Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label Unknown status NCT00650897 Phase 4 Escitalopram
27 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
28 Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Cognitive, Anxiety and Depressive Symptoms in Patients Diagnosed With Major Depressive Disorder Unknown status NCT02213016 Phase 4
29 A Randomized Controlled Study Comparing Fluoxetine With Bupropion for Impulsivity and Suicidality in Patients With Major Depressive Disorder and Comorbid Alcoholism (Abuse or Dependence) Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
30 Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
31 Behandlung Von Leichten Und Unterschwelligen Depressionen. Eine Randomisierte, Kontrollierte Studie Zum Wirksamkeitsnachweis Eines Serotonin-Wiederaufnahme-Hemmers (SSRI), Einer Kognitiven Verhaltenstherapie Und Einer Freien Therapiewahl ("Treatment of Mild and Subthreshold Depressive Disorders". A Randomized, Controlled Trial on the Efficacy of a Serotonin-Reuptake-Inhibitor (SSRI), a Cognitive-Behavioral Therapy and of Free Choice Between SSRI and CBT") Unknown status NCT00226642 Phase 4 Sertralin;Placebo
32 A Comparative Trial of TMS Approaches to Treating Depression Unknown status NCT01906905 Phase 4
33 Sequence Towards Remission in Depression Unknown status NCT01628783 Phase 4 escitalopram 10 mg;Placebo
34 Brain Mechanisms and Targeting Insomnia in Major Depression Unknown status NCT00628914 Phase 4 escitalopram and eszopiclone;Escitalopram, eszopiclone, and placebo;Escitalopram
35 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy - a Monocentric, Double-Blind, Placebo-Controlled Trial Unknown status NCT00150839 Phase 4 Mirtazapine;Venlafaxine
36 Neurochemical,Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder Unknown status NCT02346682 Phase 4 venlafaxine
37 Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child Unknown status NCT01796132 Phase 4 SSRI/SNRI
38 A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
39 TMSFOS: Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression Unknown status NCT02042573 Phase 4 SSRI (SEROPLEX ou ZOLOFT)
40 Treatment Prediction in Adolescent and Adult Depression Unknown status NCT00106197 Phase 4 Bupropion
41 a Randomized, Double Blind, Placebo-controlled, Multicenter Clinical Trial of Efficacy and Safety of Shu Gan yi Yang Capsule in the Treatment of Depression Associated With Erectile Dysfunction (Stagnation of Liver qi and Kidney Deficiency) Unknown status NCT03290313 Phase 4 shu gan yi yang capsule;shu gan yi yang capsule simulation agent
42 A Double-Blind, Placebo-Controlled, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis Unknown status NCT01329406 Phase 4 Milnacipran;Placebo
43 Prediction of Individual Treatment Response Based on Brain Changes at the Early Phase of Antidepressant Treatment in Major Depressive Disorder Using Machine Learning Classification Analysis Unknown status NCT02330679 Phase 4 Desvenlafaxine;Placebo
44 A Randomized Controlled Trial of Antidepressant Maintenance for Major Depression Following Mild Traumatic Brain Injury Unknown status NCT00162916 Phase 4 citalopram;Placebo
45 Collaborative Care for Depressed Elders in China Unknown status NCT01287494 Phase 4 Sertraline
46 A Multicenter, Double Blind Trial to Compare the Efficacy and Safety of Escitalopram With Placebo in Patients With Acute Stroke for the Prevention of Poststroke Depression and Related Symptoms (Emotional Incontinence, Anger Proneness), and for Improvement of Neurologic, Cognitive Function and Quality of Life Unknown status NCT01278498 Phase 4 Escitalopram;sugar pill
47 Group Mindfulness-Based Cognitive Therapy for the Treatment of Late-Life Depression and Anxiety Symptoms in Primary Care: A Randomized Controlled Trial Unknown status NCT02777905 Phase 4
48 Prospective 24-week Study, Comparing Clinical Outcomes Between Switching Antidepressants and Maintaining the Same Antidepressant in Patients With Major Depressive Disorder Who do Not Show a 20% Reduction in Symptoms at Week 2 Unknown status NCT00519012 Phase 4 Sertraline to Paroxetine;Paroxetine to Sertraline
49 Phase 3 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study Unknown status NCT00426946 Phase 4 Reboxetine
50 A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Major Depressive Disorder (MDD) Unknown status NCT01556971 Phase 4 Botox;Saline Solution

Search NIH Clinical Center for Endogenous Depression

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Alprazolam
Amitriptyline
Amitriptyline Hydrochloride
Amoxapine
Bupropion
Bupropion hydrobromide
Bupropion Hydrochloride
Buspirone
buspirone hydrochloride
Citalopram
Citalopram hydrobromide
Clomipramine
Clomipramine Hydrochloride
Desipramine
Desipramine Hydrochloride
Doxepin
Doxepin Hydrochloride
Escitalopram
Escitalopram oxalate
Fluoxetine
Fluoxetine Hydrochloride
Fluvoxamine
Fluvoxamine Maleate
HYPERICUM PERFORATUM (ST. JOHN'S WORT)
Imipramine
Imipramine Hydrochloride
Imipramine pamoate
Isocarboxazid
Isoflurane
Kava preparation
Lithium
Lithium Aspartate
Lithium Carbonate
lithium citrate
Lorazepam
Maprotiline
Maprotiline Hydrochloride
Methylphenidate
Methylphenidate Hydrochloride
Mirtazapine
nefazodone
Nortriptyline
Nortriptyline Hydrochloride
Paroxetine
Paroxetine Hydrochloride
Phenelzine
Phenelzine Sulfate
Pramipexole
Pramipexole dihydrochloride
Protriptyline
Protriptyline Hydrochloride
Selegiline
selegiline hydrochloride
Sertraline
Sertraline Hydrochloride
Temazepam
Tranylcypromine
Tranylcypromine sulfate
Trazodone
Trazodone Hydrochloride
Tricyclic Antidepressant [EPC]
Trimipramine
Trimipramine Maleate
venlafaxine
Venlafaxine hydrochloride

Cochrane evidence based reviews: depressive disorder

Genetic Tests for Endogenous Depression

Anatomical Context for Endogenous Depression

MalaCards organs/tissues related to Endogenous Depression:

40
Brain, Testes, Heart, Cortex, Pituitary, Breast, Prefrontal Cortex

Publications for Endogenous Depression

Articles related to Endogenous Depression:

(show top 50) (show all 4178)
# Title Authors PMID Year
1
Different effects of pyridostigmine on the thyrotropin response to thyrotropin-releasing hormone in endogenous depression and subclinical thyrotoxicosis. 54 61
9440477 1998
2
Neuroendocrine aspects of primary endogenous depression. X: Serum growth hormone measures in patients and matched control subjects. 54 61
2111183 1990
3
Beta-lipotropin-beta-endorphin response to low-dose ovine corticotropin releasing factor in endogenous depression. Preliminary studies. 54 61
2139563 1990
4
Diagnosis, Clinical Features, and Implications of Agitated Depression. 61
32008687 2020
5
Self-criticism, interpersonal conditions, and biosystemic inflammation in suicidal thoughts and behaviors within mood disorders: A bio-cognitive-interpersonal hypothesis. 61
30447120 2020
6
[Advice Literature on Depression: How Evidence-Based is it?] 61
31158912 2020
7
Causal Pathways Between Severe Mental Illness and Behaviors Related to HIV: Patient Perspectives. 61
31535348 2020
8
[Exploring Early Maladaptative Schema (EMS) in adults with bipolar disorder: A systematic review of the scientific literature]. 61
31767255 2020
9
Alcohol Use Disorder Is Differently Associated With Psychotic Symptoms According To Underlying Psychiatric Disorders: A General Population Study. 61
31603188 2020
10
The subjective-agentic personality sector (SAPS): Introduction to the special issue on self, identity, and psychopathology. 61
31206666 2020
11
The effect of atorvastatin on cognition and mood in bipolar disorder and unipolar depression patients: A secondary analysis of a randomized controlled trial. 61
31733459 2020
12
Diet and Psychosis: A Scoping Review. 61
30359969 2020
13
Identification of Common Neural Circuit Disruptions in Emotional Processing Across Psychiatric Disorders. 61
31964160 2020
14
"Do depressive and manic symptoms differentially impact on functioning in acute depression? Results from a large, cross-sectional study". 61
31600585 2020
15
Minocycline for Depressive Symptoms: a Meta-Analysis of Randomized, Double-Blinded, Placebo-Controlled Trials. 61
31965454 2020
16
Activity and subsequent depression levels: a causal analysis of behavioural activation group treatment with weekly assessments over 8 weeks. 61
31976588 2020
17
Combination of lithium and electroconvulsive therapy (ECT) is associated with higher odds of delirium and cognitive problems in a large national sample across the United States. 61
31492631 2020
18
Cell-Coupled Long Short-Term Memory With L -Skip Fusion Mechanism for Mood Disorder Detection Through Elicited Audiovisual Features. 61
30892247 2020
19
A comparison study of metabolic profiles, immunity, and brain gray matter volumes between patients with bipolar disorder and depressive disorder. 61
32000805 2020
20
Development of the National Network of Depression Centers Mood Outcomes Program: A Multisite Platform for Measurement-Based Care. 61
31960777 2020
21
Abnormal topology of brain functional networks in unipolar depression and bipolar disorder using optimal graph thresholding. 61
31493423 2020
22
Bipolar depression: a major unsolved challenge. 61
31903509 2020
23
Morbidity and Mortality in the Children and Young Adult Offspring of Parents With Schizophrenia or Affective Disorders-A Nationwide Register-Based Cohort Study in 2 Million Individuals. 61
31173637 2020
24
Thyroid hormone treatment in the management of treatment-resistant unipolar depression: A systematic review and meta-analysis. 61
31977066 2020
25
Electroconvulsive therapy modulates grey matter increase in a hub of an affect processing network. 61
31884221 2019
26
Pharmacological interventions for treatment-resistant depression in adults. 61
31846068 2019
27
Remediating reduced memory specificity in bipolar disorder: A case study using a Computerized Memory Specificity Training. 61
31747124 2019
28
The association of trait impulsivity and suicidal ideation and its fluctuation in the context of the Interpersonal Theory of Suicide. 61
32004858 2019
29
Cellular calcium in bipolar disorder: systematic review and meta-analysis. 61
31801967 2019
30
Negative Emotions and the Course of Depression During Psychotherapy in Suicidal Older Adults With Depression and Cognitive Impairment. 61
31582195 2019
31
Body dysmorphic disorder and major depressive episode have comorbidity-independent associations with suicidality in an acute psychiatric setting. 61
31450136 2019
32
Predictors of cognitive remediation therapy improvement in (partially) remitted unipolar depression. 61
31846901 2019
33
Early identification of bipolar from unipolar depression before manic episode: Evidence from dynamic rfMRI. 61
31407477 2019
34
Differential biomarker signatures in unipolar and bipolar depression: A machine learning approach. 61
31789053 2019
35
Clinical association to FKBP5 rs1360780 in patients with depression. 61
31219960 2019
36
A deep learning framework for automatic diagnosis of unipolar depression. 61
31586827 2019
37
A 6-day combined wake and light therapy trial for unipolar depression. 61
31472393 2019
38
Chronotype, circadian rhythms and mood. 61
31786494 2019
39
Depression in Children and Adolescents: Evaluation and Treatment. 61
31730312 2019
40
A review of transcranial direct current stimulation (tDCS) for the individualized treatment of depressive symptoms. 61
31938757 2019
41
Bipolar depression: the clinical characteristics and unmet needs of a complex disorder. 61
31311335 2019
42
Working memory interacts with emotion regulation to predict symptoms of mania. 61
31525674 2019
43
A specific group of patients with diagnostic conversion from depression to bipolar disorder and finally to dementia as a mental GSK-3 disease: A hypothesis. 61
31742842 2019
44
Magnetoencephalography resting-state spectral fingerprints distinguish bipolar depression and unipolar depression. 61
31729112 2019
45
Generalizability of pharmacologic and psychotherapy trial results for late-life unipolar depression. 61
31726850 2019
46
Patients' and providers' experiences with video consultations used in the treatment of older patients with unipolar depression: A systematic review. 61
31677331 2019
47
Depression. 61
31691857 2019
48
Videoconferences and Treatment of Depression: Satisfaction Score Correlated with Number of Sessions Attended but Not with Age. 61
31670614 2019
49
Acoustic differences between healthy and depressed people: a cross-situation study. 61
31615470 2019
50
Personalise antidepressant treatment for unipolar depression combining individual choices, risks and big data (PETRUSHKA): rationale and protocol. 61
31645364 2019

Variations for Endogenous Depression

Copy number variations for Endogenous Depression from CNVD:

7 (show all 23)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 30014 1 239103312 239231293 Duplication RGS7 Depressive disorder
2 46482 10 81631178 81930681 Duplication ANXA11 Depressive disorder
3 46483 10 81631178 81930681 Duplication C10orf57 Depressive disorder
4 46484 10 81631178 81930681 Duplication PLAC9 Depressive disorder
5 46485 10 81631178 81930681 Duplication SFTPD Depressive disorder
6 49583 11 108105203 108301884 Duplication DDX10 Depressive disorder
7 96990 15 97399748 97770838 Duplication LRRC28 Depressive disorder
8 96991 15 97399748 97770838 Duplication TTC23 Depressive disorder
9 188464 4 65074807 68777792 Duplication CENPC1 Depressive disorder
10 188465 4 65074807 68777792 Duplication EPHA5 Depressive disorder
11 188466 4 65074807 68777792 Duplication GNRHR Depressive disorder
12 188467 4 65074807 68777792 Duplication STAP1 Depressive disorder
13 188468 11 117276569 117305325 Duplication TMPRSS11 Depressive disorder
14 188469 4 65074807 68777792 Duplication UBA6 Depressive disorder
15 192627 5 115261015 115369537 Duplication AP3S1 Depressive disorder
16 196524 5 168423758 169070607 Duplication CCDC99 Depressive disorder
17 196525 5 168423758 169070607 Duplication DOCK2 Depressive disorder
18 196526 5 168423758 169070607 Duplication SLIT3 Depressive disorder
19 198486 5 25121416 25298271 Duplication CDH10 Depressive disorder
20 223205 7 17201925 17473214 Duplication AHR Depressive disorder
21 223742 7 24922773 25040936 Duplication OSBPL3 Depressive disorder
22 228816 7 8241584 8363438 Duplication ICA1 Depressive disorder
23 237111 8 21188347 21318056 Duplication GFRA2 Depressive disorder

Expression for Endogenous Depression

Search GEO for disease gene expression data for Endogenous Depression.

Pathways for Endogenous Depression

Pathways related to Endogenous Depression according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.43 TRH OXT NR3C1 NPY HTR2A HTR1A
2
Show member pathways
13.18 IL2 HTR3A HTR2A HTR1A GNRH1 CREB1
3
Show member pathways
12.33 NR3C1 INS IL1B CREB1
4
Show member pathways
12.32 OXT IL1B CRHR1 CRH CREB1
6 12.05 OXT NPY HTR1A CREB1 BDNF
7 11.69 TPH1 SLC6A4 MAOA HTR3A HTR2A HTR1A
8 11.65 NR3C1 IL2 CREB1
9 11.64 IL2 CRHR1 CRH CREB1
10 11.56 IL2 IL1B BDNF
11 11.53 TPH1 SLC6A4 NR3C1 MAOA IL1B HTR3A
12
Show member pathways
11.36 NR3C1 IL2 IL1B BCL2A1
13 11.3 NR3C1 INS CREB1
14
Show member pathways
11.27 SLC6A4 MAOA IL1B
15
Show member pathways
10.94 SLC6A4 MAOA HTR1A
16 10.88 TPH1 SLC6A4 MAOA HTR3A HTR2A HTR1A
17 10.71 CREB1 BDNF
18 10.36 CRHR1 CRH

GO Terms for Endogenous Depression

Cellular components related to Endogenous Depression according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.86 OXT NPY INS IL2 IL1B GNRH1
2 extracellular region GO:0005576 9.81 TRH OXT NPY INS IL2 IL1B
3 secretory granule GO:0030141 9.5 TRH OXT IL1B
4 integral component of presynaptic membrane GO:0099056 9.13 SLC6A4 HTR3A HTR2A
5 integral component of postsynaptic membrane GO:0099055 8.8 SLC6A4 HTR3A HTR2A

Biological processes related to Endogenous Depression according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 INS IL2 IL1B HTR2A HTR1A CRH
2 aging GO:0007568 9.86 HTR2A GNRH1 CREB1 BCL2A1
3 chemical synaptic transmission GO:0007268 9.85 NPY HTR3A HTR2A HTR1A CRH
4 circadian rhythm GO:0007623 9.8 TPH1 SLC6A4 CREB1
5 cell-cell signaling GO:0007267 9.77 TRH INS IL2 IL1B GNRH1
6 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.76 NPY HTR2A HTR1A
7 positive regulation of fat cell differentiation GO:0045600 9.72 TPH1 HTR2A CREB1
8 female pregnancy GO:0007565 9.71 OXT GNRH1 CRHR1 CRH
9 response to cocaine GO:0042220 9.69 OXT HTR3A CRH
10 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.65 IL2 IL1B BCL2A1
11 response to ethanol GO:0045471 9.65 TRH IL2 HTR3A GNRH1 CRH
12 G protein-coupled receptor signaling pathway GO:0007186 9.65 TRH OXT NPY INS IL2 HTR2A
13 positive regulation of lipid biosynthetic process GO:0046889 9.62 INS CREB1
14 sleep GO:0030431 9.61 OXT HTR2A
15 behavior GO:0007610 9.61 HTR2A HTR1A
16 parturition GO:0007567 9.6 CRHR1 CRH
17 response to prostaglandin E GO:0034695 9.59 OXT GNRH1
18 negative regulation of feeding behavior GO:2000252 9.58 TRH INS
19 positive regulation of prostaglandin secretion GO:0032308 9.57 OXT IL1B
20 memory GO:0007613 9.55 SLC6A4 OXT HTR2A CREB1 BDNF
21 sperm ejaculation GO:0042713 9.54 SLC6A4 OXT
22 response to ether GO:0045472 9.52 OXT CRH
23 serotonin receptor signaling pathway GO:0007210 9.5 HTR3A HTR2A HTR1A
24 signal transduction GO:0007165 9.44 TRH OXT NR3C1 INS IL1B HTR3A
25 regulation of serotonin secretion GO:0014062 9.43 HTR1A CRH

Molecular functions related to Endogenous Depression according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.43 TRH OXT NPY INS GNRH1 CRH
2 neuropeptide hormone activity GO:0005184 9.33 OXT NPY CRH
3 serotonin binding GO:0051378 8.92 SLC6A4 HTR3A HTR2A HTR1A

Sources for Endogenous Depression

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....